Across TCGA pan-cancer cohorts, H1-2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of H1-2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where H1-2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types H1-2 is over-expressed in tumor, although a few such as LUAD and HNSC show the opposite, repressed pattern.

CCRCC, LUAD, and HNSC are the cancer types where H1-2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in H1-2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	+0.688	<.001	10	view →
LUAD	Female	III,IV	−1.460	<.001	8	view →
HNSC	All	IV	−0.403	.002	8	view →
LSCC	Male	All	−0.604	<.001	7	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: H1-2 RNA expression & survival · all H1-2 data types